SCHEMBL4837245

SCHEMBL4837245

CC(=O)NC1(c2ccccc2)CCN(CCC2c3ccccc3CCN2C(=O)C2CCCC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
MTNR1B P49286 5/20 0.44
KEAP1 Q14145 8/20 0.43
POLB P06746 1/20 0.43
NFE2L2 Q16236 4/20 0.42
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP2C19 P33261 1/20 0.40
TACR3 P29371 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4837378 0.99 ALDH1A1 (0.52) ALDH1A1NPSR1MTNR1BKEAP1POLB
SCHEMBL4833126 0.99 ALDH1A1 (0.52) ALDH1A1NPSR1MTNR1BKEAP1POLB
SCHEMBL4838204 0.91 POLB (0.42) ALDH1A1NPSR1MTNR1BKEAP1POLB
SCHEMBL4830036 0.91 CYP2C19 (0.53) ALDH1A1NPSR1MTNR1BKEAP1NFE2L2
SCHEMBL4830134 0.90 CYP2C19 (0.55) ALDH1A1NPSR1MTNR1BKEAP1CYP2C19
SCHEMBL4833547 0.86 NPSR1 (0.52) ALDH1A1NPSR1MTNR1BKEAP1NFE2L2
SCHEMBL4839169 0.86 NPSR1 (0.54) ALDH1A1NPSR1MTNR1BKEAP1NFE2L2
SCHEMBL4839028 0.84 POLB (0.43) ALDH1A1MTNR1BPOLBTACR3
SCHEMBL4839655 0.83 OPRM1 (0.46) ALDH1A1MTNR1BPOLBCYP2C19TACR3
SCHEMBL4830126 0.83 TACR3 (0.45) POLBTACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP claimed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 ALDH1A1 639/4885NPSR1 167/4885MTNR1B 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.